MADRID, 26 Dic. (EUROPA PRESS) –
The American pharmaceutical company Bristol Myers Squibb has reached an agreement under which it will acquire RayzeBio for a total value of approximately 4,100 million dollars (3,722 million euros), as announced by the company, which expects to complete the purchase in the first half of 2024.
The transaction, which was unanimously approved by the boards of directors of both companies, contemplates the payment of $62.50 in cash for each RayzeBio share, compared to $27.95 at the previous closing.
RayzeBio is a clinical-stage radiopharmaceutical therapeutics company with a portfolio of drug development programs currently targeting the treatment of solid tumors, including gastroenteropancreatic neuroendocrine tumors (GEP-NET), small cell lung cancer, hepatocellular carcinoma and other cancers.
“This transaction enhances our increasingly diversified oncology portfolio by providing a differentiated platform and portfolio, and further strengthens our growth opportunities in the second half of the decade and beyond,” said Christopher Boerner, CEO of Bristol Myers. Squibb.
